Copyright Reports & Markets. All rights reserved.

Global and China Breakthrough Therapy (BT) Designation Market 2020 by Company, Type and Application, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Breakthrough Therapy (BT) Designation Market Overview

    • 1.1 Product Overview and Scope of Breakthrough Therapy (BT) Designation
    • 1.2 Classification of Breakthrough Therapy (BT) Designation by Type
      • 1.2.1 Global Breakthrough Therapy (BT) Designation Revenue by Type: 2015 VS 2019 VS 2025
      • 1.2.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type in 2019
      • 1.2.3 Oncology
      • 1.2.4 Infectious Diseases
      • 1.2.5 Rare Diseases
      • 1.2.6 Autoimmune Diseases
      • 1.2.7 Pulmonary Diseases
      • 1.2.8 Neurological Disorders
      • 1.2.9 Others
    • 1.3 Global Breakthrough Therapy (BT) Designation Market by Application
      • 1.3.1 Overview: Global Breakthrough Therapy (BT) Designation Revenue by Application: 2015 VS 2019 VS 2025
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Research Institute
      • 1.3.5 Laboratories
    • 1.4 Global Breakthrough Therapy (BT) Designation Market by Regions
      • 1.4.1 Global Breakthrough Therapy (BT) Designation Market Size by Regions: 2015 VS 2019 VS 2025
      • 1.4.2 Global Market Size of Breakthrough Therapy (BT) Designation (2015-2025)
      • 1.4.3 North America (USA, Canada and Mexico) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
      • 1.4.4 Europe (Germany, France, UK, Russia and Italy) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
      • 1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
      • 1.4.6 South America (Brazil, Argentina, Colombia) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
      • 1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)

    2 Company Profiles

    • 2.1 Roche
      • 2.1.1 Roche Details
      • 2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.1.3 Roche SWOT Analysis
      • 2.1.4 Roche Product and Services
      • 2.1.5 Roche Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.2 Sanofi
      • 2.2.1 Sanofi Details
      • 2.2.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.2.3 Sanofi SWOT Analysis
      • 2.2.4 Sanofi Product and Services
      • 2.2.5 Sanofi Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.3 Janssen
      • 2.3.1 Janssen Details
      • 2.3.2 Janssen Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.3.3 Janssen SWOT Analysis
      • 2.3.4 Janssen Product and Services
      • 2.3.5 Janssen Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.4 Abbvie
      • 2.4.1 Abbvie Details
      • 2.4.2 Abbvie Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.4.3 Abbvie SWOT Analysis
      • 2.4.4 Abbvie Product and Services
      • 2.4.5 Abbvie Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.5 Gilead
      • 2.5.1 Gilead Details
      • 2.5.2 Gilead Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.5.3 Gilead SWOT Analysis
      • 2.5.4 Gilead Product and Services
      • 2.5.5 Gilead Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.6 Novartis International AG
      • 2.6.1 Novartis International AG Details
      • 2.6.2 Novartis International AG Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.6.3 Novartis International AG SWOT Analysis
      • 2.6.4 Novartis International AG Product and Services
      • 2.6.5 Novartis International AG Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.7 Acadia
      • 2.7.1 Acadia Details
      • 2.7.2 Acadia Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.7.3 Acadia SWOT Analysis
      • 2.7.4 Acadia Product and Services
      • 2.7.5 Acadia Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.8 Eli Lilly
      • 2.8.1 Eli Lilly Details
      • 2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.8.3 Eli Lilly SWOT Analysis
      • 2.8.4 Eli Lilly Product and Services
      • 2.8.5 Eli Lilly Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.9 BMS
      • 2.9.1 BMS Details
      • 2.9.2 BMS Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.9.3 BMS SWOT Analysis
      • 2.9.4 BMS Product and Services
      • 2.9.5 BMS Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.10 Regeneron
      • 2.10.1 Regeneron Details
      • 2.10.2 Regeneron Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.10.3 Regeneron SWOT Analysis
      • 2.10.4 Regeneron Product and Services
      • 2.10.5 Regeneron Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.11 Vertex
      • 2.11.1 Vertex Details
      • 2.11.2 Vertex Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.11.3 Vertex SWOT Analysis
      • 2.11.4 Vertex Product and Services
      • 2.11.5 Vertex Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.12 Jazz Pharmaceuticals
      • 2.12.1 Jazz Pharmaceuticals Details
      • 2.12.2 Jazz Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.12.3 Jazz Pharmaceuticals SWOT Analysis
      • 2.12.4 Jazz Pharmaceuticals Product and Services
      • 2.12.5 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.13 Boehringer Ingelheim
      • 2.13.1 Boehringer Ingelheim Details
      • 2.13.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.13.3 Boehringer Ingelheim SWOT Analysis
      • 2.13.4 Boehringer Ingelheim Product and Services
      • 2.13.5 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.14 Eisai
      • 2.14.1 Eisai Details
      • 2.14.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.14.3 Eisai SWOT Analysis
      • 2.14.4 Eisai Product and Services
      • 2.14.5 Eisai Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.15 Alexion
      • 2.15.1 Alexion Details
      • 2.15.2 Alexion Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.15.3 Alexion SWOT Analysis
      • 2.15.4 Alexion Product and Services
      • 2.15.5 Alexion Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.16 GlaxoSmithKline
      • 2.16.1 GlaxoSmithKline Details
      • 2.16.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.16.3 GlaxoSmithKline SWOT Analysis
      • 2.16.4 GlaxoSmithKline Product and Services
      • 2.16.5 GlaxoSmithKline Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.17 Amgen
      • 2.17.1 Amgen Details
      • 2.17.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.17.3 Amgen SWOT Analysis
      • 2.17.4 Amgen Product and Services
      • 2.17.5 Amgen Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.18 Exelixis
      • 2.18.1 Exelixis Details
      • 2.18.2 Exelixis Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.18.3 Exelixis SWOT Analysis
      • 2.18.4 Exelixis Product and Services
      • 2.18.3 Exelixis Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.19 Merck
      • 2.19.1 Merck Details
      • 2.19.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.19.3 Merck SWOT Analysis
      • 2.19.4 Merck Product and Services
      • 2.19.5 Merck Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.20 AstraZeneca
      • 2.20.1 AstraZeneca Details
      • 2.20.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.20.3 AstraZeneca SWOT Analysis
      • 2.20.4 AstraZeneca Product and Services
      • 2.20.5 AstraZeneca Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.21 Takeda
      • 2.21.1 Takeda Details
      • 2.21.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.21.3 Takeda SWOT Analysis
      • 2.21.4 Takeda Product and Services
      • 2.21.5 Takeda Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
    • 2.22 Pfizer
      • 2.22.1 Pfizer Details
      • 2.22.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.22.3 Pfizer SWOT Analysis
      • 2.22.4 Pfizer Product and Services
      • 2.22.5 Pfizer Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)

    3 Market Competition, by Players

    • 3.1 Global Breakthrough Therapy (BT) Designation Revenue and Share by Players (2015-2020)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Breakthrough Therapy (BT) Designation Players Market Share
      • 3.2.2 Top 10 Breakthrough Therapy (BT) Designation Players Market Share
    • 3.3 Market Competition Trend

    4 Market Size by Regions

    • 4.1 Global Breakthrough Therapy (BT) Designation Revenue and Market Share by Regions
    • 4.2 North America Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 4.3 Europe Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 4.4 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 4.5 South America Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 4.6 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

    5 North America Breakthrough Therapy (BT) Designation Revenue by Countries

    • 5.1 North America Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
    • 5.2 USA Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 5.3 Canada Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 5.4 Mexico Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

    6 Europe Breakthrough Therapy (BT) Designation Revenue by Countries

    • 6.1 Europe Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
    • 6.2 Germany Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 6.3 UK Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 6.4 France Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 6.5 Russia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 6.6 Italy Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

    7 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Countries

    • 7.1 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
    • 7.2 China Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 7.3 Japan Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 7.4 Korea Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 7.5 India Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 7.6 Southeast Asia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

    8 South America Breakthrough Therapy (BT) Designation Revenue by Countries

    • 8.1 South America Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
    • 8.2 Brazil Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 8.3 Argentina Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

    9 Middle East & Africa Revenue Breakthrough Therapy (BT) Designation by Countries

    • 9.1 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
    • 9.2 Saudi Arabia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 9.3 UAE Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 9.4 Egypt Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
    • 9.5 South Africa Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

    10 Market Size Segment by Type

    • 10.1 Global Breakthrough Therapy (BT) Designation Revenue and Market Share by Type (2015-2020)
    • 10.2 Global Breakthrough Therapy (BT) Designation Market Forecast by Type (2019-2024)
    • 10.3 Oncology Revenue Growth Rate (2015-2025)
    • 10.4 Infectious Diseases Revenue Growth Rate (2015-2025)
    • 10.5 Rare Diseases Revenue Growth Rate (2015-2025)
    • 10.6 Autoimmune Diseases Revenue Growth Rate (2015-2025)
    • 10.7 Pulmonary Diseases Revenue Growth Rate (2015-2025)
    • 10.8 Neurological Disorders Revenue Growth Rate (2015-2025)
    • 10.9 Others Revenue Growth Rate (2015-2025)

    11 Global Breakthrough Therapy (BT) Designation Market Segment by Application

    • 11.1 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Application (2015-2020)
    • 11.2 Breakthrough Therapy (BT) Designation Market Forecast by Application (2019-2024)
    • 11.3 Hospital Revenue Growth (2015-2020)
    • 11.4 Clinic Revenue Growth (2015-2020)
    • 11.5 Research Institute Revenue Growth (2015-2020)
    • 11.6 Laboratories Revenue Growth (2015-2020)

    12 Global Breakthrough Therapy (BT) Designation Market Size Forecast (2021-2025)

    • 12.1 Global Breakthrough Therapy (BT) Designation Market Size Forecast (2021-2025)
    • 12.2 Global Breakthrough Therapy (BT) Designation Market Forecast by Regions (2021-2025)
    • 12.3 North America Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
    • 12.4 Europe Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
    • 12.5 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
    • 12.6 South America Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
    • 12.7 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology
      • 14.2 Data Source
      • 14.3 Disclaimer

      Market Overview
      The global Breakthrough Therapy (BT) Designation market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.7% in the forecast period of 2020 to 2025 and will expected to reach USD 69830 million by 2025, from USD 51990 million in 2019.

      The Breakthrough Therapy (BT) Designation market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

      Market segmentation
      Breakthrough Therapy (BT) Designation market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

      By Type, Breakthrough Therapy (BT) Designation market has been segmented into:
      Oncology
      Infectious Diseases
      Rare Diseases
      Autoimmune Diseases
      Pulmonary Diseases
      Neurological Disorders
      Others

      By Application, Breakthrough Therapy (BT) Designation has been segmented into:
      Hospital
      Clinic
      Research Institute
      Laboratories

      Regions and Countries Level Analysis
      Regional analysis is another highly comprehensive part of the research and analysis study of the global Breakthrough Therapy (BT) Designation market presented in the report. This section sheds light on the sales growth of different regional and country-level Breakthrough Therapy (BT) Designation markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Breakthrough Therapy (BT) Designation market.

      The report offers in-depth assessment of the growth and other aspects of the Breakthrough Therapy (BT) Designation market in important countries (regions), including:
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Competitive Landscape and Breakthrough Therapy (BT) Designation Market Share Analysis
      Breakthrough Therapy (BT) Designation competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Breakthrough Therapy (BT) Designation sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Breakthrough Therapy (BT) Designation sales, revenue and market share for each player covered in this report.

      The major players covered in Breakthrough Therapy (BT) Designation are:
      Roche
      Sanofi
      Janssen
      Abbvie
      Gilead
      Novartis International AG
      Acadia
      Eli Lilly
      BMS
      Regeneron
      Vertex
      Jazz Pharmaceuticals
      Boehringer Ingelheim
      Eisai
      Alexion
      GlaxoSmithKline
      Amgen
      Exelixis
      Merck
      AstraZeneca
      Takeda
      Pfizer

      Buy now